However, In our study, the Kaplan–Meier analysis indicated that glioma patients with high IP6K2 expression had a poor OS outcome (Figure S1A), but had no correlation with DFS (Figure S1B). This evidence concerns the gene IP6K2 and central nervous system cancer.